- In antiviral cellular assays, antiviral potency (EC 90) of ASC11 is 31-fold of that of Nirmatrelvir, 120-fold of that of S-217622, 16-fold of that of PBI-0451 and 7-fold of that of EDP-235. - ASC11 ...

(RTTNews) - Ascletis Pharma Inc. said Wednesday that the U.S. Food and Drug Administration has approved the Investigational New Drug (IND) application of ASC11, an oral inhibitor drug candidate ...

--The Phase I clinical trial will consist of 3 cohorts in healthy subjects, including single- and multiple-dose escalation studies and food effect study. The objective of Phase I trial is to find a ...

(RTTNews) - Ascletis Pharma Inc. (ASCLF.PK) said China National Medical Products Administration has approved the Investigational New Drug application for ASC11, an oral inhibitor drug candidate ...

Ascletis Pharma Inc., an innovative R&D driven biotech company, announces that its oral small molecule drug candidate ASC11, a 3-chymotrypsin like protease (3CLpro) inhibitor, demonstrated potential ...

Ascletis Pharma Inc. announces that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of ASC11, an oral inhibitor drug candidate targeting ...

--The objective of Phase I clinical trial is to identify a safe and efficacious dose for the pivotal Phase II/III in COVID-19 patients. Phase I clinical trial is expected to be completed within the ...

-- In antiviral cellular assays with infectious SARS-CoV-2, ASC11 demonstrated higher potency against SARS-CoV-2 than other 3CLpro inhibitors including Nirmatrelvir, S-217622, PBI-0451 and EDP-235, ...